Table 4.
Independent Risk Factors for 6-Week Mortality in the HCC Subgroup with Acute Variceal Hemorrhage (n=125)
| Variable | Univariate | Multivariate using HCC stage (history of HCC, BCLC 0–B vs BCLC C–D) |
Multivariate using HCC stage (history of HCC, BCLC 0–C vs BCLC D) |
||
|---|---|---|---|---|---|
| p-value | p-value | HR (95% CI) | p-value | HR (95% CI) | |
| Heart rate <100/min | 0.015 | ||||
| Active bleeding on initial endoscopy | 0.038 | ||||
| Endoscopic hemostasis failure | <0.001 | 0.002 | 4.838 (1.741–11.033) | 0.001 | 4.136 (1.750–9.773) |
| Alanine aminotransferase, IU/L | 0.048 | ||||
| PPI use | 0.023 | ||||
| MELD score | <0.001 | 0.001 | 1.145 (1.055–1.243) | 0.005 | 1.125 (1.036–1.221) |
| HCC stage, BCLC stage (C–D vs 0–B) | <0.001 | 0.019 | 3.096 (1.204–7.960) | <0.001 | 5.129 (2.312–1.380) |
| Presence of PVT | <0.001 | ||||
| Hepatic failure | <0.001 | ||||
| Hepatorenal syndrome | 0.001 | ||||
| Hepatic encephalopathy | 0.015 | ||||
HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer; HR, hazard ratio; CI, confidence interval; PPI, proton pump inhibitor; MELD, Model for End-Stage Liver Disease; PVT, portal vein thrombosis.